Table 4 Drug treatment in children with enthesitis-related arthritis in the cohort study
From: Axial involvement in enthesitis-related arthritis: results from a single-center cohort
Drug treatment, n (%) | axial ERA (n = 57) | peripheral ERA (n = 48) | P |
|---|---|---|---|
Disease onset | |||
NSAID | 57 (100) | 48 (100) | - |
DMARD | 57 (100) | 45 (93.75) | 0.184 |
Biologics | 38 (66.67) | 10 (20.83) | 0.000* |
Biologics combined with DMARDs | 38 (66.67) | 10 (20.83) | 0.000* |
6-month follow-up | |||
NSAID | 53 (92.30) | 45 (93.75) | 1.000 |
DMARD | 57 (100) | 48 (100) | - |
Biologics | 39 (68.42) | 16 (33.33) | 0.000* |
Biologics combined with DMARDs | 39 (68.42) | 16 (33.33) | 0.000* |
12-month follow-up | |||
NSAID | 53 (92.30) | 37 (77.08) | 0.020* |
DMARD | 56 (98.25) | 45 (93.75) | 0.492 |
Biologics | 39 (68.42) | 13 (27.08) | 0.000* |
Biologics combined with DMARDs | 39 (68.42) | 13 (27.08) | 0.000* |
18-month follow-up | |||
NSAID | 43 (75.44) | 30 (62.5) | 0.151 |
DMARD | 57 (100) | 44 (91.67) | 0.087 |
Biologics | 41 (71.93) | 12 (25) | 0.000* |
Biologics combined with DMARDs | 41 (71.93) | 12 (25) | 0.000* |
End of follow-up | |||
NSAID | 31 (54.39) | 22 (45.83) | 0.383 |
DMARD | 47 (82.46) | 35 (72.92) | 0.239 |
Biologics | 31 (54.39) | 5 (10.42) | 0.000* |
Biologics combined with DMARDs | 31 (54.39) | 4 (8.33) | 0.000* |